Stock KYTX KYVERNA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Delayed Nasdaq
Other stock markets
 15:55:13 2024-05-31 EDT 		5-day change 1st Jan Change
12.58 USD +2.07% Intraday chart for Kyverna Therapeutics, Inc. -3.15% 0.00%
05-14 Kyverna Therapeutics Q1 Loss Narrows MT
05-14 Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Kyverna Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

05.ISICq9bXjn8ANvRto_rtVS0Q9wOHhWJCVrNhHGIpJhY.b2964uOAtztmBrkY78rfHERRllax0AApJ_4scRJiSWNmRkzFk7y9T0pbrQ~390b059ceb7520bfcb62d03e0e0e4030

Analyst Recommendations on Kyverna Therapeutics, Inc.

JPMorgan Initiates Kyverna Therapeutics With Overweight Rating MT
Morgan Stanley Starts Kyverna Therapeutics With Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.32 USD
Average target price
42.75 USD
Spread / Average Target
+247.00%
High Price Target
48 USD
Spread / Highest target
+289.61%
Low Price Target
39 USD
Spread / Lowest Target
+216.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kyverna Therapeutics, Inc.

Morgan Stanley
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KYTX Stock
  4. Consensus Kyverna Therapeutics, Inc.